Sustained desensitization of hypothalamic 5-hydroxytryptamine(1A) receptors after discontinuation of fluoxetine: Inhibited neuroendocrine responses to 8-hydroxy-2-(dipropylamino)tetralin in the absence of changes in G(i/o/z) proteins

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 2, 1999, Pages 561-567

  Raap, D K ^a   Garcia, F ^a   Muma, N A ^a   Wolf, W A ^a,b   Battaglia, G ^a   Van De Kar, Louis D ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; FLUOXETINE; NORFLUOXETINE; OXYTOCIN; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CORTICOTROPIN RELEASE; DOSE TIME EFFECT RELATION; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; MALE; NONHUMAN; OXYTOCIN RELEASE; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ADRENOCORTICOTROPIC HORMONE; ANIMALS; BRAIN; DRUG INTERACTIONS; FLUOXETINE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HYPOTHALAMUS; MALE; OXYTOCIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SENSITIVITY AND SPECIFICITY; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0032986894     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Auerbach SB and Hjorth S (1995) Effect of chronic administration of the selective serotonin (5-HT) uptake inhibitor citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo. Naunyn-Schmiedeberg's Arch Pharmacol 352:597-606.
2. 2C receptor-mediated oxytocin, prolactin and ACTH/corticosterone responses. Behav Brain Res 73:277-280.
3. Barr AJ, Brass LF and Manning DR (1997) Reconstitution of receptors and GTP-binding regulatory proteins (G proteins) in Sf9 cells. A direct evaluation of selectivity in receptor.G protein coupling. J Biol Chem 272:2223-2229.
4. Caccia S, Cappi M, Fracasso C and Garattini S (1990) Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology 100:509-514.
5. Caccia S, Fracasso C, Garattini S, Guiso G and Sarati S (1992) Effects of short-and long-term administration of fluoxetine on the monoamine content of rat brain. Neuropharmacology 31:343-347.
6. Caccia S, Confalonieri S, Bergami A, Fracasso C, Anelli M and Garattini S (1997) Neuropharmacological effects of low and high doses of repeated oral dexfenfluramine in rats: A comparison with fluoxetine. Pharmacol Biochem Behav 57:851-856.
7. Calogero AE, Bernardini R, Margioris AN, Bagdy G, Gallucci WT, Tamarkin L and Tomai TP (1989) Effect of serotonergic agonists and antagonists on corticotropin-releasing hormone secretion by explanted rat hypothalami. Peptides 10:189-200.
8. Cole BJ, Cador M, Stinus L, Rivier C, Rivier J, Vale W, Le Moal M and Koob GF (1990) Critical role of the hypothalamic pituitary adrenal axis in amphetamine-induced sensitization of behavior. Life Sci 47:1715-1720.
9. Coupland NJ, Bell CJ and Potokar JP (1996) Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 16:356-362.
10. DeVane CL (1994) Pharmacokinetics of the newer antidepressants: Clinical relevance. Am J Med 97 (Suppl 6A):13S-23S.
11. Fields TA and Casey PJ (1995) Phosphorylation of Gz alpha by protein kinase C blocks interaction with the beta gamma complex. J Biol Chem 270:23119-23125.
12. Fuller RW (1996) Mechanisms and functions of serotonin neuronal systems -Opportunities for neuropeptide interactions. Ann NY Acad Sci 780:176-184.
13. Gardier AM, Lepoul E, Trouvin JH, Chanut E, Dessalles MC and Jacquot C (1994) Changes in dopamine metabolism in rat forebrain regions after cessation of long-term fluoxetine treatment: Relationship with brain concentrations of fluoxetine and norfluoxetine. Life Sci 54:PL51-PL56.
14. 1A receptor subtype increases rat plasma ACTH concentration. Eur J Pharmacol 147:431-439.
15. Hallak H, Brass LF and Manning DR (1994) Failure to myristoylate the alpha subunit of Gz is correlated with an inhibition of palmitoylation and membrane attachment, but has no effect on phosphorylation by protein kinase C. J Biol Chem 269:4571-4576.
16. Ho MK and Wong YH (1997) Functional role of amino-terminal serine16 and serine27 of G alphaZ in receptor and effector coupling. J Neurochem 68:2514-2522.
17. Kreiss DS and Lucki I (1995) Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther 274:866-876.
18. 1A autoreceptors in rats treated with fluoxetine or paroxetine. Naunyn-Schmiedeberg's Arch Pharmacol 352:141-148.
19. Lerer B, Gelfin Y and Gorfine M (1997) Temperature and hormone responses of normal subjects to ipsapirone challenge: Effect of fluoxetine treatment. Psychoneuroendocrinology 22:166.
20. 1A receptor responsivity in obsessive-compulsive disorder. Psychopharmacology 105:415-420.
21. Levy AD, Li Q, Gustafson M and Van de Kar LD (1995) Neuroendocrine profile of the potential anxiolytic drug S-20499. Eur J Pharmacol 274:141-149.
22. Li Q, Brownfield MS, Battaglia G, Cabrera TM, Levy AD, Rittenhouse PA and Van de Kar LD (1993a) Long-term treatment with the antidepressants fluoxetine and desipramine potentiates endocrine responses to the serotonin agonists 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) and (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCI (DOI). J Pharmacol Exp Ther 266:836-844.
23. 1A agonist 8-OH-DPAT in male rats. Brain Res 630:148-156.
24. 1A agonist ipsapirone by long-term treatment with fluoxetine, but not desipramine, in male rats. Biol Psychiatry 36:300-308.
25. 1A agonist. J Pharmacol Exp Ther 279:1035-1042.
26. 1A receptors. J Pharmacol Exp Ther 282:1581-1590.
27. 1A receptor-mediated neuroendocrine responses to 8-OH-DPAT. Soc Neurosci Abst 23:385.5.
28. j proteins. J Pharmacol Exp Ther, 288, in press.
29. sα. Biochemistry 32:11064-11073.
30. 1A receptor sensitivity. Psychopharmacology 132:296-302.
31. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH and Zajecka J (1997a) Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. J Clin Psychiatry 58 (Suppl 7):23-27.
32. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH and Zajecka J (1997b) Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. Discontinuation Consensus Panel. J Clin Psychiatry 58 (Suppl 7):5-10.
33. 1A agonist 8-OH-DPAT. Soc Neurosci Abst 24:539.18.
34. Steel RGD and Torrie JH (1960) Principles and Procedures of Statistics with Special Reference to the Biological Sciences, McGraw-Hill, New York.
35. 3H]-5-hydroxytryptamine and [3H]-spiperone binding in rat frontal cortex and serotonin receptor mediated behaviour. Psychopharmacology 80:150-155.
36. Trouvin JH, Gardier AM, Chanut E, Pages N and Jacquot C (1993) Time course of brain serotonin metabolism after cessation of long-term fluoxetine treatment in the rat. Life Sci 52:PL187-PL192.
37. z GAP and other RGS proteins by palmitoylation of G protein α subunits. Science 278:1132-1135.
38. Turnbull AV and Rivier C (1997) Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein, and related peptides. Proc Soc Exp Biol Med 215:1-10.
39. 1A agonist and potential anxiolytic drug alnespirone (S-20499). Pharmacol Biachem Behav 61:677-683.
40. 1A receptor-mediated increase in oxytocin and ACTH secretion. Soc Neurosci Abst 24:539.17.
41. Vicentic A, Li Q, Battaglia G and Van de Kar LD (1998) WAY-100635 inhibits 8-OH-DPAT stimulated oxytocin, ACTH, and corticosterone, but not prolactin secretion. Eur J Pharmacol 346:261-266.
42. Wong DT, Bymaster FP, Horng JS and Molloy BB (1975) A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-Trifluoromethylphenoxy)-n-methyl-3-phenylpropylamine. J Pharmacol Exp Ther 193:804-811.
43. Zajecka J, Tracy KA and Mitchell S (1997) Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review. J Clin. Psychiatry 58:291-297.